When treating premature infants for Respiratory Distress Syndrome (RDS)

CUROSURF® (poractant alfa)
Delivers Fast RDS Success

Why choose CUROSURF for your NICU?

Checkered flag

Fast onset1,2*

See FiO2 reductions and oxygenation improvements with CUROSURF.

Vial

Single-dose success3,4†

Review the data: In clinical studies, most infants required only 1 dose of CUROSURF.

Arrows pointing down

Lowest volume5†

See how CUROSURF delivers more surfactant with less volume.

 
Review Clinical DataCare TPink arrow icon.
  
 
*Not proven to impact clinical outcomes such as mortality.
†Not established to result in superior safety or efficacy.
#1 most-used surfactant in the US

The #1 Surfactant Used in US NICUs6‡

With more than 25 years of clinical research and more than 4.2 million infants treated worldwide, CUROSURF is used by more NICUs than any other surfactant.6,7

Learn About Our ExperiencePink arrow icon.Pink arrow icon.
  
 
‡Please note that this metric only provides insight into the surfactant selected by NICUs and does not imply equivalence or superiority between or among the products for any given clinical endpoint.
Mother and infant icon

Why and When to Consider Early Rescue

The decision for early rescue with exogenous surfactant in respiratory distress syndrome (RDS) is multifactorial, based on both infant characteristics and maternal factors. Understanding those characteristics can help identify increased risk for CPAP failure, allowing proactive management in the NICU.8,9

Learn About Early Rescue in RDSPink arrow icon.Pink arrow icon.
IMPORTANT SAFETY INFORMATION

CUROSURF® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700–2000 g birth weight with RDS requiring mechanical ventilation and FiO2 ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial emphysema (21% vs. 38%).

INDICATION

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Please see Full Prescribing Information.

CPAP=continuous positive airway pressure; FiO2=fraction of inspired oxygen; NICU=neonatal intensive care unit.

References: 1. Speer CP, Gefeller O, Groneck P, et al. Arch Dis Child. 1995;72(1):F8-F13. 2. Collaborative European Multicenter Study Group. Pediatrics. 1988;82(5):683-691. 3. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; North American Study Group. Am J Perinatol. 2004;21(3):109-119. 4. Verder H, Albertsen P, Ebbesen F, et al. Pediatrics. 1999;103(2):E24. 5. Gerdes JS, Seiberlich W, Sivieri EM, et al. J Pediatr Pharmacol Ther. 2006;11(2):92-100. 6. IQVIA Global Market Share, Total Year 2018. 7. Data on file, Chiesi Farmaceutici S.p.A. and Chiesi USA, Inc. 8. Nanda D, Nangia S, Thukral A, et al. Eur J Pediatr. 2020;179(4):603-610. 9. Tian T, Wang L, Ye R, et al. Pregnancy Hypertens. 2020;19:131-137.